Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis

Free Subscription Articles published in Dig Dis Sci Retrieve available abstracts of 45 articles: HTML format

Single Articles

May 2023
1. CZAJA AJ
   Incorporating the Molecular Mimicry of Environmental Antigens into the Causality of Autoimmune Hepatitis.
   Dig Dis Sci. 2023 May 9. doi: 10.1007/s10620-023-07967.
   PubMed     Abstract available
   
   
   April 2023
2. RUSTAM LB, Vander Weg M, Chrischilles E, Tanaka T, et al
   Sociodemographic and Clinical Factors Associated with Nonattendance at the Hepatology Clinic.
   Dig Dis Sci. 2023 Apr 27. doi: 10.1007/s10620-023-07951.
   PubMed     Abstract available
   
   
   
3. WANG CL, Huang CH, Wu VC, Wu CL, et al
   Prognostic Effects of Liver Fibrosis and Steatosis Determined Using Transient Elastography in Patients with Chronic Hepatitis B or C.
   Dig Dis Sci. 2023 Apr 18. doi: 10.1007/s10620-023-07943.
   PubMed     Abstract available
   
   
   
4. MAJEED NA, Alawad AS, Liem KS, Takyar V, et al
   Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy.
   Dig Dis Sci. 2023 Apr 6. doi: 10.1007/s10620-023-07916.
   PubMed     Abstract available
   
   
   February 2023
5. BONKOVSKY HL, Rudnick SP, Ma CD, Overbey JR, et al
   Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.
   Dig Dis Sci. 2023 Feb 22. doi: 10.1007/s10620-023-07859.
   PubMed     Abstract available
   
   
   
6. MA GX, Zhu L, Tan Y, Zhai S, et al
   A Comparative Trial of Improving Care for Underserved Asian Americans Infected with Hepatitis B Virus.
   Dig Dis Sci. 2023 Feb 7. doi: 10.1007/s10620-023-07840.
   PubMed     Abstract available
   
   
   
7. MATEOS-MUNOZ B, Buti M, Vazquez IF, Conde MH, et al
   Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B.
   Dig Dis Sci. 2023 Feb 3. doi: 10.1007/s10620-022-07817.
   PubMed     Abstract available
   
   
   
8. CHIU SM, Chang KC, Hu TH, Hung CH, et al
   Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
   Dig Dis Sci. 2023;68:665-675.
   PubMed     Abstract available
   
   
   December 2022
9. XU J, Wang Y, Feng H, Liu F, et al
   HBV/HCV Infection Was Not Significantly Independently Associated with COVID-19 Severity: A Meta-Analysis of Confounding Variables-Adjusted Data.
   Dig Dis Sci. 2022 Dec 23:1-3. doi: 10.1007/s10620-022-07799.
   PubMed    
   
   
   
10. JINDAL A, Agarwal S, Sharma S, Kumar M, et al
    Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease.
    Dig Dis Sci. 2022 Dec 23. doi: 10.1007/s10620-022-07778.
    PubMed     Abstract available
    
    
    
11. TAHATA Y, Sakamori R, Yamada R, Kodama T, et al
    Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis.
    Dig Dis Sci. 2022 Dec 16. doi: 10.1007/s10620-022-07629.
    PubMed     Abstract available
    
    
    October 2022
12. CZAJA AJ
    Missing Causality and Heritability of Autoimmune Hepatitis.
    Dig Dis Sci. 2022 Oct 19. pii: 10.1007/s10620-022-07728.
    PubMed     Abstract available
    
    
    
13. LIU YC, Cheng YT, Chen YC, Hsieh YC, et al
    Correction: Comparing Predictability of Noninvasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients.
    Dig Dis Sci. 2022 Oct 17. pii: 10.1007/s10620-022-07683.
    PubMed    
    
    
    
14. LIU CH, Jiang W, Wu DB, Zeng QM, et al
    Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection.
    Dig Dis Sci. 2022 Oct 13. pii: 10.1007/s10620-022-07695.
    PubMed     Abstract available
    
    
    September 2022
15. HONMA Y, Shibata M, Morino K, Koya Y, et al
    Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C.
    Dig Dis Sci. 2022 Sep 14. pii: 10.1007/s10620-022-07686.
    PubMed     Abstract available
    
    
    
16. YU Y, Li X, Wan T
    Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis.
    Dig Dis Sci. 2022 Sep 9. pii: 10.1007/s10620-022-07687.
    PubMed     Abstract available
    
    
    July 2022
17. LIU YC, Cheng YT, Chen YC, Hsieh YC, et al
    Comparing Predictability of Non-invasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients Characters: 102 (< 120).
    Dig Dis Sci. 2022 Jul 27. pii: 10.1007/s10620-022-07621.
    PubMed     Abstract available
    
    
    
18. YARRA P, Dunn W, Younossi Z, Kuo YF, et al
    Association of Previous Gastric Bypass Surgery and Patient Outcomes in Alcohol-Associated Cirrhosis Hospitalizations.
    Dig Dis Sci. 2022 Jul 4. pii: 10.1007/s10620-022-07591.
    PubMed     Abstract available
    
    
    
19. FANG HW, Yen YH, Hung CH, Wang JH, et al
    Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir.
    Dig Dis Sci. 2022;67:3402-3411.
    PubMed     Abstract available
    
    
    June 2022
20. BERNSTEIN DE, Trinh HN, Schiff ER, Smith CI, et al
    Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
    Dig Dis Sci. 2022;67:2637-2645.
    PubMed     Abstract available
    
    
    May 2022
21. LLOYD C, Leighton J, Wong LL, Goulding A, et al
    Patient Priorities in Autoimmune Hepatitis: The Need for Better Treatments, More Education and Challenging Stigma.
    Dig Dis Sci. 2022 May 17. pii: 10.1007/s10620-022-07525.
    PubMed     Abstract available
    
    
    
22. CLARK PJ, Valery PC, Strasser SI, Weltman M, et al
    Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort.
    Dig Dis Sci. 2022 May 13. pii: 10.1007/s10620-022-07483.
    PubMed     Abstract available
    
    
    
23. RAO A, Rule JA, Cerro-Chiang G, Stravitz RT, et al
    Role of Hepatitis C Infection in Acute Liver Injury/Acute Liver Failure in North America.
    Dig Dis Sci. 2022 May 11. pii: 10.1007/s10620-022-07524.
    PubMed     Abstract available
    
    
    
24. SHROFF H, Fix OK
    Autoimmune Hepatitis-Like Syndrome Following COVID-19 Vaccination: Real or Imagined?
    Dig Dis Sci. 2022 May 9. pii: 10.1007/s10620-022-07509.
    PubMed    
    
    
    April 2022
25. CHOW KW, Pham NV, Ibrahim BM, Hong K, et al
    Autoimmune Hepatitis-Like Syndrome Following COVID-19 Vaccination: A Systematic Review of the Literature.
    Dig Dis Sci. 2022 Apr 29. pii: 10.1007/s10620-022-07504.
    PubMed     Abstract available
    
    
    
26. JONES E, Watkins M, Anderson E, Gelow K, et al
    Overlooked Symptoms in Autoimmune Hepatitis Negatively Impact Many Facets of Life.
    Dig Dis Sci. 2022 Apr 19. pii: 10.1007/s10620-022-07484.
    PubMed     Abstract available
    
    
    March 2022
27. ANIEMEKA C, Pillai AA
    HCC Mortality Trends-In with ALD (and NAFLD) and Out with HCV.
    Dig Dis Sci. 2022 Mar 14. pii: 10.1007/s10620-022-07434.
    PubMed    
    
    
    
28. RAMANI A, Tapper EB, Griffin C, Shankar N, et al
    Hepatocellular Carcinoma-Related Mortality in the USA, 1999-2018.
    Dig Dis Sci. 2022 Mar 14. pii: 10.1007/s10620-022-07433.
    PubMed     Abstract available
    
    
    
29. MAK LY, Wong DK, Cheung KS, Hui RW, et al
    Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection.
    Dig Dis Sci. 2022 Mar 8. pii: 10.1007/s10620-022-07429.
    PubMed     Abstract available
    
    
    
30. SAAB S, Pham N, Wu W, Dang L, et al
    Spontaneous Seroclearance Is Associated with Lower Liver Fibrosis in Treatment-Naive Chronic Hepatitis B Patients.
    Dig Dis Sci. 2022 Mar 4. pii: 10.1007/s10620-022-07402.
    PubMed     Abstract available
    
    
    February 2022
31. CZAJA AJ
    Advancing Biologic Therapy for Refractory Autoimmune Hepatitis.
    Dig Dis Sci. 2022 Feb 11. pii: 10.1007/s10620-021-07378.
    PubMed     Abstract available
    
    
    January 2022
32. PANCHAL SA, Kaplan DE, Goldberg DS, Mahmud N, et al
    Algorithms to Identify Alcoholic Hepatitis Hospitalizations in Patients with Cirrhosis.
    Dig Dis Sci. 2022 Jan 13. pii: 10.1007/s10620-021-07321.
    PubMed     Abstract available
    
    
    November 2021
33. CHANG JI, Sinn DH, Cho H, Kim S, et al
    Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels.
    Dig Dis Sci. 2021 Nov 20. pii: 10.1007/s10620-021-07312.
    PubMed     Abstract available
    
    
    September 2021
34. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B.
    Dig Dis Sci. 2021 Sep 2. pii: 10.1007/s10620-021-07157.
    PubMed     Abstract available
    
    
    July 2021
35. VAZ K, Little R, Majeed A, Kemp W, et al
    Determinants of Short- and Long-Term Outcomes of an Australian Cohort of Patients Admitted with Alcoholic Hepatitis.
    Dig Dis Sci. 2021 Jul 6. pii: 10.1007/s10620-021-07140.
    PubMed     Abstract available
    
    
    
36. TOKA B, Koksal AS, Eminler AT, Tozlu M, et al
    Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation.
    Dig Dis Sci. 2021;66:2417-2426.
    PubMed     Abstract available
    
    
    June 2021
37. GELOW K, Chalasani S, Green K, Lammert C, et al
    Utilization and Impact of Complementary and Alternative Medicines in Symptomatic Autoimmune Hepatitis Patients.
    Dig Dis Sci. 2021 Jun 23. pii: 10.1007/s10620-021-07112.
    PubMed     Abstract available
    
    
    May 2021
38. CHEN J, Hubbard A, Bagley L, Shiau R, et al
    Prevalence of Latent Tuberculosis Infection Among Persons with Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis.
    Dig Dis Sci. 2021 May 30. pii: 10.1007/s10620-021-07056.
    PubMed     Abstract available
    
    
    
39. PINYOPORNPANISH K, Al-Yaman W, Dasarathy S, Romero-Marrero C, et al
    Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival.
    Dig Dis Sci. 2021 May 23. pii: 10.1007/s10620-021-07048.
    PubMed     Abstract available
    
    
    
40. LIN MH, Li HQ, Zhu L, Su HY, et al
    Liver Fibrosis in the Natural Course of Chronic Hepatitis B Viral Infection: A Systematic Review with Meta-Analysis.
    Dig Dis Sci. 2021 May 18. pii: 10.1007/s10620-021-07009.
    PubMed     Abstract available
    
    
    
41. HE WQ, Matthews GV, Liu B
    Characteristics Associated with Monitoring and Treatment of Chronic Hepatitis B in a Large Cohort of Australian Adults.
    Dig Dis Sci. 2021 May 4. pii: 10.1007/s10620-021-07008.
    PubMed     Abstract available
    
    
    April 2021
42. LAMMERT C, Chalasani SN, Green K, Atkinson E, et al
    Patients with Autoimmune Hepatitis Report Lower Lifetime Coffee Consumption.
    Dig Dis Sci. 2021 Apr 30. pii: 10.1007/s10620-021-06989.
    PubMed     Abstract available
    
    
    
43. CZAJA AJ
    Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis.
    Dig Dis Sci. 2021 Apr 9. pii: 10.1007/s10620-021-06968.
    PubMed     Abstract available
    
    
    
44. CHANG PE, Tan CK, Cheah CC, Li W, et al
    Validation of the Expanded Baveno-VI Criteria for Screening Gastroscopy in Asian Patients with Compensated Advanced Chronic Liver Disease.
    Dig Dis Sci. 2021;66:1343-1348.
    PubMed     Abstract available
    
    
    February 2021
45. STERLING RK, King WC, Khalili M, Kleiner DE, et al
    Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults.
    Dig Dis Sci. 2021 Feb 8. pii: 10.1007/s10620-021-06860.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: